MiniMed™ 740G System

With SmartGuard™ technology



MiniMed™ mobile app

Easily tracks sugar levels and notifies on smart phone if your patients are going high or low.

Care partners can also download the CareLink™ Connect app to stay in the know.

Accu-Chek® Guide Link blood glucose meter

Accurate test results from the blood glucose meter are sent wirelessly to the pump for quick sensor calibrations.

Predicts and prevents lows before your patients ever feel them.

CareLink™ software

Provides insights that support meaningful conversations with your patients. Manage and share your data with personalised diabetes insights to power your therapy decisions.

Guardian™ Sensor 3

Continuous Glucose Monitoring (CGM) sensor measures sugar levels every 5 minutes, sending info to the pump.

Now with Bluetooth® connectivity

Can provide advanced protection from hypoglycaemia, compared to CSII therapy:[1]

- 73% less hypoglycaemias
- 79% less time spent in hypoglycaemias
- 84% less severe hypoglycaemias
- Lower rate of nocturnal hypoglycaemias

Medtronic

MiniMed™ 740G System
With SmartGuard™ technology

With MiniMed™ 740G system with SmartGuard™ technology, your patients could prevent over 80% of severe hypoglycaemic events without a significant increase in hypoglycaemia.[2] It can help reduce the frequency of both high and low sensor glucose values and help stabilise sensor glucose after resumption of insulin delivery.[3] Sensor-augmented insulin pump therapy with the threshold-suspend feature reduces nocturnal hypoglycaemia.[4] Most of SmartGuard™ technology predicted hypoglycaemic events did not reach the pre-set low limit.[3]

SmartGuard™ technology helps[1] prevent lows to give your patients more control



SmartGuard™ technology
Suspends insulin
when sensor glucose (SG) is predicted to go low.

SmartGuard™ technology
Resumes basal insulin
when SG recovers.

Insulin suspended window (suspended up to 2 hours)

SG readings

SmartGuard™ technology can significantly reduce the risk for hypoglycemia in pediatric Type 1 Diabetes patients without increasing HbA1c.[5]

REFERENCES

1. Bosi E, et al. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemiaprone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial. Lancet Diabetes Endocrinol 2019;7: 462–72.
2. Choudhary P, et al. Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management Diabetes Technol Ther. 2016; 18(5):288-291.
3. Zhong A. et al. Effectiveness of Automated Insulin Management Features of the Medtronic 640G Sensor- Augmented Insulin Pump. Diabetes Technol Ther. 2016; 18(10): 657-663.
4. Bergenstal RM, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. The New England Journal of Medicine 2013;369(3):224-232.
5. Biester T. et al. "Let the Algorithm Do the Work": Reduction of Hypoglycemia Using Sensor- Augmented Pump Therapy with Predictive Insulin Suspension (SmartGuard) in Pediatric Type 1 Diabetes Patients. Diabetes Technol Ther. 2017; 19(3):173-182.

*MiniMed™ 740G and the MiniMed™ 640G system share the same therapy algorithm.

Medtronic